Advair (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 53 Pages
|Advair(氣喘):市場預測與分析 Advair (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 53 Pages||
Advair是由GSK所開發的丙酸Fluticasone及salmeterol xinafoate的FDC(固定劑量複方藥物)。丙酸Fluticasone是具有強力消炎作用的合成皮質類固醇。Fluticasone可與糖皮質激素受體以高度親和性結合，抑制氣喘相關媒介物(組織胺，類花生酸，白三烯，細胞激素等)的分泌。具有比budenoside3倍、二丙酸氯地米松活性代謝物2倍的效能。同時salmeterol xinafoate也是高度選擇性LABA(長效型β2刺激藥)。
GlobalData has released its new PharmaPoint Drug Evaluation report, "Advair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate. Salmeterol xinafoate is a highly selective LABA.